Recap: Immunogen Q3 Earnings

Shares of Immunogen IMGN rose 3.3% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 13.33% year over year to ($0.13), which beat the estimate of ($0.18).

Revenue of $18,189,000 up by 36.96% from the same period last year, which beat the estimate of $15,360,000.

Guidance

Immunogen hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Nov 06, 2020

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/64s8quyx

Technicals

52-week high: $7.07

52-week low: $1.95

Price action over last quarter: Up 50.06%

Company Description

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.